Pathophysiology
The study [PMID:41565669] highlights that T. trichiura infection profoundly disrupts gut microbial structure and function, anchoring in the colonic mucosa and triggering immune responses that alter the microbiota [PMID:41565669].
Epidemiology
More than 360 million people are chronically infected with T. trichiura, primarily in resource-poor regions of Southeast Asia, Sub-Saharan Africa, and the tropical regions of the Americas [PMID:35197976].
The discovery of Trichuris incognita n sp in Côte d'Ivoire suggests that regional differences in Trichuris species distribution could impact the epidemiology and public health strategies for trichuriasis [PMID:41655578].
Clinical Presentation
Given the impact of T. trichiura on gut microbiota, clinical presentations may include gastrointestinal symptoms indicative of dysbiosis, such as changes in bowel habits and abdominal pain [PMID:41565669].
The infection leads to malnutrition, diarrhea, anemia, and in severe cases, rectal prolapse [PMID:35197976].
The study highlights that children in rural, resource-limited settings, particularly those aged 2-5 years, are at high risk of trichuris trichiura infections, which can impair physical and cognitive development [PMID:40975108].
Diagnosis
The study utilized genomic and morphological analyses to distinguish Trichuris incognita n sp, indicating that advanced diagnostic techniques can refine species identification in trichuriasis cases [PMID:41655578].
Management
Effective management of trichuriasis might benefit from interventions aimed at restoring gut microbiota balance, in addition to standard antiparasitic therapies [PMID:41565669].
Anthelmintic treatment, particularly mass drug administration with albendazole or mebendazole, is promoted by WHO for controlling STH infections, including trichuriasis [PMID:35197976].
Analysis of Trichuris incognita n sp in Côte d'Ivoire revealed differences in sensitivity to the standard anthelmintic combination of albendazole and ivermectin [PMID:41655578]. This underscores the potential need for region-specific treatment protocols beyond the current combination therapy.
In a randomized controlled trial, children aged 2-5 years with trichuris trichiura infections were treated with orodispersible ivermectin at doses of 100 μg/kg, 200 μg/kg, 300 μg/kg, and 400 μg/kg co-administered with 400 mg albendazole, demonstrating varying levels of efficacy [PMID:40975108].
The study aimed to identify the optimal dose of ivermectin for treating trichuris trichiura infections in children aged 2-5 years, indicating that higher doses may be more effective but further research is needed to confirm [PMID:40975108].
References
1 Schneeberger PHH, Dommann J, Rahman N, Hürlimann E, Sayasone S, Ali S et al.. Profound taxonomic and functional gut microbiota alterations associated with trichuriasis: cross-country and country-specific patterns. NPJ biofilms and microbiomes 2026. link 2 Wei J, Hegde VL, Yanamandra AV, O'Hara MP, Keegan B, Jones KM et al.. Mucosal Vaccination With Recombinant . Frontiers in immunology 2022. link 3 Bär MA, Kouamé NA, Touré S, Coulibaly JT, Schneeberger PHH, Keiser J. Characterisation of Trichuris incognita n sp in Côte d'Ivoire: a morphological, genomic, and genome-wide association with drug sensitivity study. The Lancet. Microbe 2026. link 4 Sprecher VP, Schnoz A, Biendl S, Hussein HS, Najim SO, Ali MN et al.. Efficacy and safety of ascending doses of orodispersible ivermectin co-administered with albendazole for Trichuris trichiura infections in preschool-aged children in Tanzania: a single-blind, randomised, controlled, dose-ranging, phase 2 trial. The Lancet. Infectious diseases 2026. link00472-4)